文献速递抗栓抗凝管理药物不良反应与药物警戒

碳酸氢盐基冲洗液用于Impella心室辅助装置的病例系列分析

A case series analysis of bicarbonate-based purge solution administration via Impella ventricular assist device.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

3例(17%)发生Impella相关并发症,其中2例发生在BBPS治疗超过21天后。BBPS为无法耐受肝素的患者提供可行选择,但装置长期耐用性仍需进一步数据。

要点

  • BBPS可用于肝素不耐受或禁忌的Impella患者,主要适应症为大出血和凝血病。
  • 2例并发症发生在BBPS治疗超过21天后,提示需关注长期使用风险。

核心结论

  • BBPS为无法耐受肝素基冲洗液的Impella患者提供可行选择,但需进一步数据确定装置长期耐用性以降低并发症风险。

主要发现

  • BBPS适应症为凝血病5例(28%)、疑似HIT 2例(11%)、确诊HIT 1例(6%)、大出血10例(56%)。
  • 3例(17%)在BBPS期间发生Impella并发症:1例需泵更换,1例需移除装置,1例因疑似冲洗液阻塞接受alteplase。
  • 2例并发症发生在BBPS治疗超过21天后。

临床怎么用

  • 对肝素不耐受或禁忌的Impella患者可考虑BBPS作为替代冲洗液。
  • BBPS使用超过21天时需警惕Impella相关并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Impella device historically required a heparin-based purge solution to reduce the risk of biomaterial deposition to maintain pump function. In April 2022, the Food and Drug Administration approved utilization of bicarbonate-based purge solutions (BBPS) as an alternative to heparin for patients who are intolerant to heparin or in whom heparin is contraindicated. The purpose of this case series is to report patient outcomes of Impella support with BBPS use at our institution. SUMMARY: Eighteen patients who received BBPS via the Impella CP or Impella 5.5 device were included in our review. Patients were included if they had BBPS administration for greater than 24 hours. All patients were followed for 72 hours after cessation of BBPS. Indications for BBPS were coagulopathy (n = 5, 28%), suspected HIT (n = 2, 11%), confirmed HIT (n = 1, 6%), and major bleeding (n = 10, 56%). Three patients (17%) experienced an Impella complication while on BBPS. One patient required pump exchange, one required removal of the Impella device, and one received alteplase for suspected purge block. Of these, two patients experienced complications greater than 21 days into BBPS therapy. CONCLUSION: This case series adds to the literature describing clinical outcomes for patients on Impella support with BBPS. While BBPS offers a viable option for the management of patients on Impella devices who are unable to tolerate heparin-based purge solutions, further data is needed to determine the longevity of the Impella device with BBPS to minimize risk of Impella complications.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Sigala MI, Harris JE, Morton C, et al. A case series analysis of bicarbonate-based purge solution administration via Impella ventricular assist device. Am J Health Syst Pharm. 2024. PMID: 37952169. doi:10.1093/ajhp/zxad278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。